Nabriva Therapeutics plc
NBRV
Rang in aandelen
#39898
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
Aandeelprijs
$0.63
Laatst gesynchroniseerd: 2023-08-29
Marktkapitalisatie
$284.20K
Verandering (1 dag)
-21.25%
Verandering (1 jaar)
629,900.02%
Land
IE
Handel Nabriva Therapeutics plc (NBRV)
Categorie
Healthcare
Koersgeschiedenis voor Nabriva Therapeutics plc (NBRV)
Hoogste slotkoers: $0.00 op 2026-10-01
Laagste slotkoers: $0.74 op 2023-08-01
Laagste slotkoers: $0.74 op 2023-08-01
Koersgeschiedenis van Nabriva Therapeutics plc van 2023 tot 2026
Jaarlijkse koersprestatie
| Jaar | Prestaties |
|---|---|
| 2026 (TTM) | 0.00% |
| 2025 | 60.55% |
| 2024 | 9.75% |
| 2023 | 0.00% |
Aandelenkoers van vergelijkbare bedrijven of concurrenten
| Bedrijf | Aandelenkoers | Verandering 1jr% | Land |
|---|---|---|---|
| $527.18 | 23.62% |
US
|
|
| $251.29 | 835.90% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $890.85 | 9.42% |
NL
|
|
| $765.98 | 8.87% |
CH
|
